EGRP News Flash - April 15, 2009

Limit on Number of Competitive Revision Applications and New GO Grant Priority Areas

On behalf of the National Cancer Institute (NCI), the Epidemiology and Genetics Research Program (EGRP) would like to share some additional information that may be of interest to cancer epidemiologists about NIH funding opportunities made available through the American Recovery and Reinvestment Act of 2009 (ARRA):

Summary information follows:

Only One Competitive Revision Application May Be Submitted for Each Parent Grant

Investigators should be aware that only one competitive revision application (formerly called competitive supplement) may be submitted for each parent grant in applying for funds made available to NIH through the ARRA. If the parent grant is a multi-component award (P01, P30, etc.), competitive revision applications for all components must be submitted as a single application with the Program Director/Principal Investigator (PD/PI) of the overall parent grant named as the PD/PI.

It is important that investigators refer to NIH's Frequently Asked QuestionsExternal Web Site Policy (FAQs); the NIH Guide for Grants and Contracts Notice NOT-OD-09-058External Web Site Policy; and the NCI Recovery Act Funding AnnouncementsExternal Web Site Policy.

Three Additional Grant Opportunities (GO Grants) Announced in Comparative Effectiveness Research and Detection of Oral Lesions Research

Under the Grant Opportunities (GO grants) program, NCI released this week information about two new priority areas in comparative effectiveness research, and the National Institute for Dental and Craniofacial Research (NIDCR) has announced its interest in supporting research on detection of oral premalignant and malignant lesions.

The GO grants program is to support high impact ideas that lend themselves to short-term, non-renewable funding, and which may lay the foundation for new fields of investigation. Letters of Intent are due by April 27, 2009, and applications are due by May 27, 2009.

  1. Comparative Effectiveness Research in Cancer Prevention, Screening and Treatment -- NCI will support 2-year efforts to build capacity and accelerate scientific progress in the area of cancer comparative effectiveness research (CER) in cancer prevention, screening, and treatment. This funding opportunity will sponsor efforts to build coherent teams of interdisciplinary researchers, leverage and integrate existing data and health system research resources, and advance measurement techniques and methodology. In order to accomplish these goals, some or all of the following aims could be addressed:
    • Health technology monitoring and assessment;
    • Evaluation, development, validation, and integration of comparative effectiveness data resources and informatics resources;
    • Development of comparative effectiveness trials resources and operating procedures;
    • Development, evaluation and validation of statistical, psychometric, econometric, informatics, and modeling methods for comparative effectiveness research; and
    • Comparative effectiveness studies.
  2. Comparative Effectiveness Research in Genomic and Personalized Medicine -- NCI also will support 2-year efforts that will advance methods for analysis, synthesis, modeling, and evaluation of the clinical validity and utility of existing and emerging genomics and personalized medicine applications in cancer control and prevention; accelerate the development of genomics and personalized medicine by planning CER initiatives; and enhance clinical and population data infrastructure to support CER initiatives in genomics and personalized medicine. In order to accomplish these goals, some or all of the following areas could be addressed:
    • Develop and apply techniques and quantitative methods for analyzing and synthesizing evidence from basic, clinical, and population sciences on genetic factors in cancer and the comparative effectiveness of genomics and personalized medicine; and
    • Plan and implement proof of principles multidisciplinary initiatives for clinical and population studies, both observational studies and clinical trials.

For each of the above two GO grants funding opportunities, NCI expects to make 3-5 awards for a period of 2 years. The budget cap for each award proposal is $2 million in total costs per year.

Applications requesting support for the above scientific areas MUST follow the guidelines listed in the NIH Guide Notice RFA-OD-09-004External Web Site Policy. Also see NCI's guidelines for the GO grants program. (See "NCI Guidelines for ARRA Research and Research Infrastructure Grand Opportunities: Comparative Effectiveness Research in Cancer Prevention, Screening and Treatment" and "NCI Guidelines for ARRA Research and Research Infrastructure Grand Opportunities: Comparative Effectiveness Research in Genomic and Personalized Medicine."

  1. Detection of Oral Premalignant and Malignant Lesions Research -- One of NIDCR's high-priority areas under the GO grants program is research on detection of oral premalignant and malignant lesions. The Institute seeks projects that will provide preliminary data that will allow for planning of definitive randomized clinical trial(s) to support or refute the role of available cancer screening techniques as an evidence-based U.S. public health intervention. Responsive projects will give special consideration to higher risk populations, such as individuals over 50 years of age, tobacco users and alcohol users, and those infected orally with human papillomavirus. NIDCR's high-priority scientific areas for this programExternal Web Site Policy.

Reminder: Organizations Must Register in Both and eRA Commons to Apply for Most NIH Grants

Please be aware that organizations seeking NIH grant support MUST register in both and eRA Commons to apply for most NIH grants. Registration can take about 4 weeks to complete.

Return to Top